 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 03/21/2000 | | | | Nymox's AD7C Test Found to be Highly Attractive and Useful in New Journal Publication
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
KENSINGTON, MD (Mar 21, 2000) -- A new peer- reviewed article in the scientific journal Alzheimer's Reports has affirmed the value of the AD7C™ test currently being provided by Nymox Pharmaceutical Corporation (NASDAQ:NYMX) exclusively through its CLIA-certified reference laboratory in Kensington, Maryland. |
| 03/14/2000 | | | | Nymox Completes Private Placement of $4.0 Million
topic: Financial
KENSINGTON, MD (March 14, 2000) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced that it has completed a private placement with an institutional investor of 666,667 shares and 66,667 warrants for total proceeds of $4.0 million. This new equity investment was placed by Ladenburg Thalmann & Co. of New York. |
| 03/08/2000 | | | | Nymox Finalizes Acquisition of Majority Interest in Serex, Inc.
topic: Financial
KENSINGTON, MD (March 8, 2000) -- Nymox
Pharmaceutical Corporation (NASDAQ:NYMX) announced today that it has finalized
the acquisition of majority ownership of Serex, Inc., a privately held company
headquartered in Maywood, NJ, in a share exchange agreement. |
| 03/01/2000 | | | | Two Recently Published Books Cite Value of Nymox's AD7C™ Test As Aid in Early Detection and Diagnosis of Alzheimer's Disease
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
KENSINGTON, MD (March 1, 2000) Two recently published books addressing the prevention, intervention and treatment of Alzheimer’s Disease discuss the benefits of the AD7C™ laboratory test which is offered for sale by Nymox Pharmaceutical Corp., the company said. |
| 02/02/2000 | | | | Co-Founders of American Academy of Anti-Aging Medicine Laud Value of Nymox's Alzheimer's Developments
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
KENSINGTON, MD (Feb. 2, 2000) Dr. Robert Goldman and Dr. Ronald
Klatz, co-founders of the American Academy of Anti-Aging Medicine, laud the research into the cause
of Alzheimer's Disease and tests to aid in its diagnosis developed by Nymox Pharmaceutical Corp.
in the new edition of their widely praised book on the brain and aging, "Brain Fitness," published by Doubleday. |
| 02/01/2000 | | | | Diagnosing Memory Loss
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
"Diagnosing Memory Loss" appeared in The Saturday Evening Post Jan./Feb. 2000 issue, page 38
Diagnosing Memory Loss
The first noninvasive laboratory test to aid physicians in the diagnosis of Alzheimer's disease is now available. |
| 01/13/2000 | | | | Nymox Gaining Recognition as Scientific Advances Continue
topic: Marketing
KENSINGTON, MD (Jan 13, 2000) -- Increasing
understanding in the scientific and medical communities of scientific advances by Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is leading
to increased recognition for the company's efforts, according to Dr. Paul Averback, president and chief executive officer. |
| 12/08/1999 | | | | Nymox Scientists Find Additional Evidence That Spherons Are Cause of Alzheimer's Disease
topic: R&D: Spherons and Alzheimer's Disease
KENSINGTON, MD (Dec 8, 1999) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced that new
investigations of Spherons have confirmed previous studies linking Spherons to the cause of Alzheimer's disease (AD). |
| 12/06/1999 | | | | Nymox's New E. Coli Treatment Shows Promising Results
topic: R&D: E coli and Other Antibacterial Treatments
December 6, 1999: Nymox Pharmaceutical Corporation today announced that its new treatment for E. coli infection (O157:H7) has shown promising results at several independent sites. The company has started the new treatment in pivotal trials which are aimed to be completed early in 2000. |
| 11/18/1999 | | | | Nymox to Trade Exclusively on Nasdaq
topic: Financial
KENSINGTON, MD (Nov 18, 1999) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced that the Company has decided to no longer have its shares traded on the
Montreal Exchange. This will take place effective after the close of business on November 19, 1999. |
|